Prevalence and trends in transmitted and acquired antiretroviral drug resistance, Washington, DC, 1999–2014

by Annette M. Aldous, Amanda D. Castel, David M. Parenti, the DC Cohort Executive Committee
Published 2017-09-01

Despite early Medicaid expansion, decreased durable virologic suppression among publicly insured people with HIV in Washington, DC: a retrospective analysis

by Deborah Goldstein, W. David Hardy, Anne Monroe, Qingjiang Hou, Rachel Hart, Arpi Terzian, on behalf of the DC Cohort Executive Committee
Published 2020-04-01

Use of national standards to monitor HIV care and treatment in a high prevalence city-Washington, DC.

by Amanda D Castel, Arpi Terzian, Rachel Hart, Nabil Rayeed, Mariah M Kalmin, Heather Young, Alan E Greenberg, DC Cohort Executive Committee
Published 2017-01-01

Validation of publicly-available software used in analyzing NGS data for HIV-1 drug resistance mutations and transmission networks in a Washington, DC, Cohort.

by Kamwing Jair, Chase D McCann, Harrison Reed, Amanda D Castel, Marcos Pérez-Losada, Brittany Wilbourn, Alan E Greenberg, Jeanne A Jordan, DC Cohort Executive Committee
Published 2019-01-01

Characterization of HIV diversity, phylodynamics and drug resistance in Washington, DC.

by Marcos Pérez-Losada, Amanda D Castel, Brittany Lewis, Michael Kharfen, Charles P Cartwright, Bruce Huang, Taylor Maxwell, Alan E Greenberg, Keith A Crandall, DC Cohort Executive Committee
Published 2017-01-01